Advantages of surface ablation debated

Article

The pros and cons of surface ablation procedures were reviewed at the opening session of the refractive surgery subspecialty day at the American Academy of Ophthalmology annual meeting.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
A panel discussion on extended treatment intervals in retinal therapy breaks the mold at COPHy 2025
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
How embracing opposition sends clinicians home from COPHy with more useful takeaways
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Angiogenesis 2025: The global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
Veterinary ophthalmology can foster insights and progress in glaucoma care
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
I. Paul Singh, MD, says artificial intelligence will help glaucoma specialists make decisions
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Charles Wykoff, MD, PhD, presents on diabetic retinopathy and "the dream of reperfusion" at Floretina ICOOR 2024
How a gene-agnostic approach opens doors to new therapeutics
How a gene-agnostic approach opens doors to new therapeutics
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
AAO 2024: Main takeaways from the Zoster Eye Disease study
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
AAO 2024: New data illuminate glaucoma care paradigms for surgical interventions
AAO 2024: Chloroprocaine ophthalmic gel as anesthesia for intravitreal injections
AAO 2024: Chloroprocaine ophthalmic gel as anesthesia for intravitreal injections
Related Content
A map of Europe with a digital overlay. Concept image for European EU commercialisation and CE mark. Image credit: ©garrykillian – stock.adobe.com

Canalicular gel Lacrifill (Nordic Pharma) receives CE Mark

Hattie Hayes
April 7th 2025
Article

Nordic Pharma plans to announce commercialisation details in the near future for the dry eye disease treatment

Higher molar dose and its translation into clinical practice. Led by John Kitchens, MD; Joined by Peter Kaiser, MD

Higher Molar Dose and Its Translation into Clinical Practice

John Kitchens, MD;Peter Kaiser, MD
July 22nd 2024
Podcast
An image of Plaza de Espana Square in Seville, Spain. Seville is home to the 2025 Congress on Controversies in Ophthalmology. Image credit: ©Anibal Trejo – stock.adobe.com

Surgical, medical and next-generation retina topics at COPHy

Hattie Hayes
April 4th 2025
Article

Retina topics serve as the backbone of the scientific programme at this year’s Congress on Controversies in Ophthalmology

A flip-calendar shows March 31st as the date, while the United States Food and Drug Administration and European Medicines Agency logos hover above. Image credit: ©Jenn Miranda, via Canva. FDA and EMA logos courtesy respective agencies.

Retina recap: EMA and US FDA approvals, March 2025

Sydney M Crago
April 3rd 2025
Article

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

A screenshot of the United States Food and Drug Administration (FDA) web page. US FDA Complete Response Letter CRL concept. Image credit: ©Jarretera – stock.adobe.com

US FDA issues second Complete Response Letter for dry eye drug reproxalap (Aldeyra Therapeutics)

Martin David Harp
April 3rd 2025
Article

Aldeyra previously received a CRL for its initial New Drug Application for reproxalap in November 2023

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp
April 2nd 2025
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

© 2025 MJH Life Sciences

All rights reserved.